Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
N Marx, MJ Davies, PJ Grant, C Mathieu… - The lancet Diabetes & …, 2021 - thelancet.com
Cardiovascular outcome trials in patients with type 2 diabetes at high cardiovascular risk
have led to remarkable advances in our understanding of the effectiveness of GLP-1 …
have led to remarkable advances in our understanding of the effectiveness of GLP-1 …
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
Clinical question What are the benefits and harms of sodium-glucose cotransporter 2 (SGLT-
2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual …
2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual …
2022 Canadian Cardiovascular Society guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults
GBJ Mancini, E O'Meara, S Zieroth, M Bernier… - Canadian Journal of …, 2022 - Elsevier
This guideline synthesizes clinical trial data supporting the role of glucagon-like peptide-1
receptor agonists and sodium-glucose co-transporter 2 inhibitors (SGLT2i) for treatment of …
receptor agonists and sodium-glucose co-transporter 2 inhibitors (SGLT2i) for treatment of …
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
E Brown, HJL Heerspink, DJ Cuthbertson, JPH Wilding - The Lancet, 2021 - thelancet.com
SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …
glucose lowering therapies, with additional benefits of weight loss and blood pressure …
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
M Lugner, N Sattar, M Miftaraj, J Ekelund… - Cardiovascular …, 2021 - Springer
Background Major prospective randomized clinical safety trials have demonstrated
beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and …
beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and …
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
SV Arnold, F Tang, A Cooper, H Chen… - BMC Endocrine …, 2022 - Springer
Background Despite strong evidence of benefit, uptake of newer glucose-lowering
medications that reduce cardiovascular risk has been low. We sought to examine global …
medications that reduce cardiovascular risk has been low. We sought to examine global …
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
G Schernthaner, N Shehadeh, AS Ametov… - Cardiovascular …, 2020 - Springer
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study
Background Current treatment guidelines do not provide recommendations to support the
selection of treatment for most people with type 2 diabetes. We aimed to develop and …
selection of treatment for most people with type 2 diabetes. We aimed to develop and …
Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus
AA Nargesi, GP Jeyashanmugaraja… - Journal of the …, 2021 - Am Heart Assoc
Background SGLT‐2 (sodium glucose transporter‐2) inhibitors and GLP‐1RAs (glucagon‐
like peptide‐1 receptor agonists) effectively lowered cardiovascular risk in large clinical trials …
like peptide‐1 receptor agonists) effectively lowered cardiovascular risk in large clinical trials …
GLP‐1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta‐analysis including the REWIND and PIONEER 6 trials
A meta‐analysis of cardiovascular outcome trials (CVOTs) comparing glucagon‐like peptide‐
1 receptor agonists (GLP‐1RAs) and placebo concerning cardiorenal outcomes in patients …
1 receptor agonists (GLP‐1RAs) and placebo concerning cardiorenal outcomes in patients …